Sign in

What researchers published on Mantle cell lymphoma

2,638 papers, newest first.

Showing 20 of 349

  • Meta-analysisClinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.Journal of managed care & specialty pharmacy
  • Review[Advances in single cell omics applications in mantle cell lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • Meta-analysisComparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine
  • ReviewHigh time for risk-adapted treatment in mantle cell lymphoma.The Lancet. Haematology
  • ReviewBTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.Cancers
  • Systematic reviewCAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.Frontiers in oncology
  • ReviewRefining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.Expert review of hematology
  • Review[Recent advances and future perspectives in the treatment of mantle cell lymphoma].[Rinsho ketsueki] The Japanese journal of clinical hematology
  • ReviewEvolution of mantle cell lymphoma therapy: advancing frontline precision.Trends in cancer
  • ReviewFirst-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.Current oncology (Toronto, Ont.)
  • ReviewMantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.European journal of haematology
  • Systematic reviewAn unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.Journal of medical economics
  • ReviewAdvances in targeted and cellular therapies for relapsed/refractory mantle cell lymphoma: immunotherapeutic strategies and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • ReviewThe preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.Expert opinion on drug discovery
  • ReviewIn mantle cell lymphoma, whether 18 F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value.Annals of hematology
  • ReviewSOHO State of the Art Updates and Next Questions | Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?Clinical lymphoma, myeloma & leukemia
  • Systematic reviewAssociation Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.Clinical lymphoma, myeloma & leukemia
  • ReviewModern Management of Mantle Cell Lymphoma.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
  • ReviewExtracellular Vesicles in B-Cell Non-Hodgkin Lymphomas: Pathogenesis, Therapeutic Implications, and Biomarker Potential.Biomedicines
  • ReviewSonrotoclax: First Approval.Drugs
Mantle cell lymphoma: what researchers published – Frontlight Research